For both cohorts, the standard NACT contained series of FEC or EC followed by series of taxanes (docetaxel or paclitaxel) and, in the case of HER2-positive tumour, combined with HER2 blockade (trastuzumab/pertuzumab). This evidence concerns the gene ERBB2 and neoplasm.